RBM10, a New Regulator of p53
Abstract
:1. Introduction
2. The MDM2-MDMX-p53 Loop
3. Regulation of the p53-MDM2-MDMX Loop
3.1. Ribosomal Proteins-p53-MDM2 Pathway
3.2. AMPK-MDMX-p53 Pathway in Cancer Cells
4. Tumor Suppressive Functions of RBM10 in Cancer Cells
5. RBM10 is an Activator of p53
6. Conclusions and Questions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Nguyen, D.; Liao, W.; Zeng, S.X.; Lu, H. Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol. Ther. 2017, 178, 92–108. [Google Scholar] [CrossRef] [PubMed]
- Lu, H. Legends of p53: Untold four-decade stories. J. Mol. Cell Biol. 2019, 11, 521–522. [Google Scholar] [CrossRef] [PubMed]
- Meek, D.W. Regulation of the p53 response and its relationship to cancer. Biochem. J. 2015, 469, 325–346. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Lu, H. Signaling to p53: Ribosomal proteins find their way. Cancer Cell 2009, 16, 369–377. [Google Scholar] [CrossRef] [Green Version]
- Kastenhuber, E.R.; Lowe, S.W. Putting p53 in Context. Cell 2017, 170, 1062–1078. [Google Scholar] [CrossRef] [Green Version]
- Jung, J.H.; Lee, H.; Kim, J.H.; Sim, D.Y.; Ahn, H.; Kim, B.; Chang, S.; Kim, S.H. p53-Dependent Apoptotic Effect of Puromycin via Binding of Ribosomal Protein L5 and L11 to MDM2 and its Combination Effect with RITA or Doxorubicin. Cancers 2019, 11, 582. [Google Scholar] [CrossRef] [Green Version]
- Vousden, K.H.; Lane, D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275–283. [Google Scholar] [CrossRef]
- Vousden, K.H.; Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137, 413–431. [Google Scholar] [CrossRef] [Green Version]
- Chipuk, J.E.; Kuwana, T.; Bouchier-Hayes, L.; Droin, N.M.; Newmeyer, D.D.; Schuler, M.; Green, D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303, 1010–1014. [Google Scholar] [CrossRef] [Green Version]
- Kiryu-Seo, S.; Hirayama, T.; Kato, R.; Kiyama, H. Noxa is a critical mediator of p53-dependent motor neuron death after nerve injury in adult mouse. J. Neurosci. 2005, 25, 1442–1447. [Google Scholar] [CrossRef]
- Leu, J.I.; Dumont, P.; Hafey, M.; Murphy, M.E.; George, D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6, 443–450. [Google Scholar] [CrossRef] [PubMed]
- Crighton, D.; Wilkinson, S.; O’Prey, J.; Syed, N.; Smith, P.; Harrison, P.R.; Gasco, M.; Garrone, O.; Crook, T.; Ryan, K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126, 121–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Green, D.R.; Kroemer, G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458, 1127–1130. [Google Scholar] [CrossRef] [PubMed]
- El-Deiry, W.S.; Tokino, T.; Velculescu, V.E.; Levy, D.B.; Parsons, R.; Trent, J.M.; Lin, D.; Mercer, W.E.; Kinzler, K.W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817–825. [Google Scholar] [CrossRef]
- Waldman, T.; Kinzler, K.W.; Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55, 5187–5190. [Google Scholar]
- Liu, M.; Casimiro, M.C.; Wang, C.; Shirley, L.A.; Jiao, X.; Katiyar, S.; Ju, X.; Li, Z.; Yu, Z.; Zhou, J.; et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 19035–19039. [Google Scholar] [CrossRef] [Green Version]
- Wu, G.; Wang, F.; Li, K.; Li, S.; Zhao, C.; Fan, C.; Wang, J. Significance of TP53 mutation in bladder cancer disease progression and drug selection. PeerJ 2019, 7, e8261. [Google Scholar] [CrossRef] [Green Version]
- Ham, S.W.; Jeon, H.Y.; Jin, X.; Kim, E.J.; Kim, J.K.; Shin, Y.J.; Lee, Y.; Kim, S.H.; Lee, S.Y.; Seo, S.; et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019, 26, 409–425. [Google Scholar] [CrossRef] [Green Version]
- Ganci, F.; Pulito, C.; Valsoni, S.; Sacconi, A.; Turco, C.; Vahabi, M.; Manciocco, V.; Mazza, E.M.C.; Meens, J.; Karamboulas, C.; et al. PI3K Inhibitors Curtail MYC-dependent Mutant p53 Gain-of-function in Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 2020, 26, 2956–2971. [Google Scholar] [CrossRef] [Green Version]
- Liao, P.; Zeng, S.X.; Zhou, X.; Chen, T.; Zhou, F.; Cao, B.; Jung, J.H.; Del Sal, G.; Luo, S.; Lu, H. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Mol. Cell. 2017, 68, 1134–1146. [Google Scholar] [CrossRef] [Green Version]
- Coleman, M.P.; Ambrose, H.J.; Carrel, L.; Nemeth, A.H.; Willard, H.F.; Davies, K.E. A novel gene, DXS8237E, lies within 20 kb upstream of UBE1 in Xp11.23 and has a different X inactivation status. Genomics 1996, 31, 135–138. [Google Scholar] [CrossRef] [PubMed]
- Timmer, T.; Terpstra, P.; van den Berg, A.; Veldhuis, P.M.; Ter Elst, A.; van der Veen, A.Y.; Kok, K.; Naylor, S.L.; Buys, C.H. An evolutionary rearrangement of the Xp11.3-11.23 region in 3p21.3, a region frequently deleted in a variety of cancers. Genomics 1999, 60, 238–240. [Google Scholar] [CrossRef] [PubMed]
- Gripp, K.W.; Hopkins, E.; Johnston, J.J.; Krause, C.; Dobyns, W.B.; Biesecker, L.G. Long-term survival in TARP syndrome and confirmation of RBM10 as the disease-causing gene. Am. J. Med. Genet. A 2011, 155A, 2516–2520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.; Gogol-Doring, A.; Hu, H.; Frohler, S.; Ma, Y.; Jens, M.; Maaskola, J.; Murakawa, Y.; Quedenau, C.; Landthaler, M.; et al. Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. EMBO Mol. Med. 2013, 5, 1431–1442. [Google Scholar] [CrossRef] [PubMed]
- Inoue, A.; Yamamoto, N.; Kimura, M.; Nishio, K.; Yamane, H.; Nakajima, K. RBM10 regulates alternative splicing. FEBS Lett. 2014, 588, 942–947. [Google Scholar] [CrossRef] [Green Version]
- Inoue, A.; Tsugawa, K.; Tokunaga, K.; Takahashi, K.P.; Uni, S.; Kimura, M.; Nishio, K.; Yamamoto, N.; Honda, K.; Watanabe, T.; et al. S1-1 nuclear domains: Characterization and dynamics as a function of transcriptional activity. Biol. Cell 2008, 100, 523–535. [Google Scholar] [CrossRef]
- Bonnal, S.; Martinez, C.; Forch, P.; Bachi, A.; Wilm, M.; Valcarcel, J. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol. Cell 2008, 32, 81–95. [Google Scholar] [CrossRef]
- Loiselle, J.J.; Roy, J.G.; Sutherland, L.C. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS ONE 2017, 12, e0180258. [Google Scholar] [CrossRef] [Green Version]
- Sun, Y.; Bao, Y.; Han, W.; Song, F.; Shen, X.; Zhao, J.; Zuo, J.; Saffen, D.; Chen, W.; Wang, Z.; et al. Autoregulation of RBM10 and cross-regulation of RBM10/RBM5 via alternative splicing-coupled nonsense-mediated decay. Nucleic Acids Res. 2017, 45, 8524–8540. [Google Scholar] [CrossRef]
- Mohan, N.; Kumar, V.; Kandala, D.T.; Kartha, C.C.; Laishram, R.S. A Splicing-Independent Function of RBM10 Controls Specific 3’ UTR Processing to Regulate Cardiac Hypertrophy. Cell Rep. 2018, 24, 3539–3553. [Google Scholar] [CrossRef] [Green Version]
- Johnston, J.J.; Teer, J.K.; Cherukuri, P.F.; Hansen, N.F.; Loftus, S.K.; Center, N.I.H.I.S.; Chong, K.; Mullikin, J.C.; Biesecker, L.G. Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate. Am. J. Hum. Genet. 2010, 86, 743–748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dou, X.Q.; Chen, X.J.; Wen, M.X.; Zhang, S.Z.; Zhou, Q.; Zhang, S.Q. Alternative splicing of VEGFA is regulated by RBM10 in endometrial cancer. Kaohsiung J. Med. Sci. 2020, 36, 13–19. [Google Scholar] [CrossRef]
- Zheng, S.; Damoiseaux, R.; Chen, L.; Black, D.L. A broadly applicable high-throughput screening strategy identifies new regulators of Dlg4 (Psd-95) alternative splicing. Genome Res. 2013, 23, 998–1007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sutherland, L.C.; Thibault, P.; Durand, M.; Lapointe, E.; Knee, J.M.; Beauvais, A.; Kalatskaya, I.; Hunt, S.C.; Loiselle, J.J.; Roy, J.G.; et al. Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA. BMC Mol. Biol. 2017, 18, 19. [Google Scholar] [CrossRef] [PubMed]
- Bechara, E.G.; Sebestyen, E.; Bernardis, I.; Eyras, E.; Valcarcel, J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 2013, 52, 720–733. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mueller, C.F.; Berger, A.; Zimmer, S.; Tiyerili, V.; Nickenig, G. The heterogenous nuclear riboprotein S1-1 regulates AT1 receptor gene expression via transcriptional and posttranscriptional mechanisms. Arch. Biochem. Biophys. 2009, 488, 76–82. [Google Scholar] [CrossRef]
- Yamada, H.; Tsutsumi, K.; Nakazawa, Y.; Shibagaki, Y.; Hattori, S.; Ohta, Y. Src Family Tyrosine Kinase Signaling Regulates FilGAP through Association with RBM10. PLoS ONE 2016, 11, e0146593. [Google Scholar] [CrossRef]
- Loiselle, J.J.; Sutherland, L.C. RBM10: Harmful or helpful-many factors to consider. J. Cell Biochem. 2018, 119, 3809–3818. [Google Scholar] [CrossRef] [Green Version]
- Aubrey, B.J.; Kelly, G.L.; Janic, A.; Herold, M.J.; Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018, 25, 104–113. [Google Scholar] [CrossRef] [Green Version]
- Rogel, A.; Popliker, M.; Webb, C.G.; Oren, M. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell Biol. 1985, 5, 2851–2855. [Google Scholar] [CrossRef]
- Manfredi, J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010, 24, 1580–1589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296–299. [Google Scholar] [CrossRef] [PubMed]
- Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25–27. [Google Scholar] [CrossRef] [Green Version]
- Fang, S.; Jensen, J.P.; Ludwig, R.L.; Vousden, K.H.; Weissman, A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000, 275, 8945–8951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moll, U.M.; Petrenko, O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1, 1001–1008. [Google Scholar]
- Bottger, V.; Bottger, A.; Garcia-Echeverria, C.; Ramos, Y.F.; van der Eb, A.J.; Jochemsen, A.G.; Lane, D.P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999, 18, 189–199. [Google Scholar] [CrossRef] [Green Version]
- Stad, R.; Little, N.A.; Xirodimas, D.P.; Frenk, R.; van der Eb, A.J.; Lane, D.P.; Saville, M.K.; Jochemsen, A.G. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2001, 2, 1029–1034. [Google Scholar] [CrossRef] [Green Version]
- Poyurovsky, M.V.; Priest, C.; Kentsis, A.; Borden, K.L.; Pan, Z.Q.; Pavletich, N.; Prives, C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007, 26, 90–101. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Wang, J.; Jiang, X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 2011, 286, 23725–23734. [Google Scholar] [CrossRef] [Green Version]
- Sharp, D.A.; Kratowicz, S.A.; Sank, M.J.; George, D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 1999, 274, 38189–38196. [Google Scholar] [CrossRef] [Green Version]
- Jackson, M.W.; Berberich, S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell Biol. 2000, 20, 1001–1007. [Google Scholar] [CrossRef] [Green Version]
- Wade, M.; Li, Y.C.; Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13, 83–96. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Zeng, S.X.; Hao, Q.; Lu, H. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Dev. Biol. 2017, 423, 34–45. [Google Scholar] [CrossRef] [PubMed]
- Shadfan, M.; Lopez-Pajares, V.; Yuan, Z.M. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res. 2012, 1, 88–89. [Google Scholar] [PubMed]
- Tackmann, N.R.; Zhang, Y. Mouse modelling of the MDM2/MDMX-p53 signalling axis. J. Mol. Cell Biol. 2017, 9, 34–44. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.; Yan, Z.; Liao, X.; Li, Y.; Yang, J.; Wang, Z.G.; Zuo, Y.; Kawai, H.; Shadfan, M.; Ganapathy, S.; et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. USA 2011, 108, 12001–12006. [Google Scholar] [CrossRef] [Green Version]
- Linke, K.; Mace, P.D.; Smith, C.A.; Vaux, D.L.; Silke, J.; Day, C.L. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008, 15, 841–848. [Google Scholar] [CrossRef] [Green Version]
- Iyappan, S.; Wollscheid, H.P.; Rojas-Fernandez, A.; Marquardt, A.; Tang, H.C.; Singh, R.K.; Scheffner, M. Turning the RING domain protein MdmX into an active ubiquitin-protein ligase. J. Biol. Chem. 2010, 285, 33065–33072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yee, K.S.; Vousden, K.H. Complicating the complexity of p53. Carcinogenesis 2005, 26, 1317–1322. [Google Scholar] [CrossRef] [PubMed]
- Appella, E.; Anderson, C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 2001, 268, 2764–2772. [Google Scholar] [CrossRef]
- Liu, Y.; Tavana, O.; Gu, W. p53 modifications: Exquisite decorations of the powerful guardian. J. Mol. Cell Biol. 2019, 11, 564–577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brooks, C.L.; Gu, W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011, 2, 456–462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gu, W.; Luo, J.; Brooks, C.L.; Nikolaev, A.Y.; Li, M. Dynamics of the p53 acetylation pathway. Novartis Found. Symp. 2004, 259, 197–205. [Google Scholar]
- Gu, W.; Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90, 595–606. [Google Scholar] [CrossRef] [Green Version]
- Li, M.; Luo, J.; Brooks, C.L.; Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol Chem. 2002, 277, 50607–50611. [Google Scholar] [CrossRef] [Green Version]
- Gu, W.; Shi, X.L.; Roeder, R.G. Synergistic activation of transcription by CBP and p53. Nature 1997, 387, 819–823. [Google Scholar] [CrossRef] [PubMed]
- Dai, C.; Shi, D.; Gu, W. Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING finger domains 1). J. Biol. Chem. 2013, 288, 19581–19592. [Google Scholar] [CrossRef] [Green Version]
- Kobet, E.; Zeng, X.; Zhu, Y.; Keller, D.; Lu, H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 2000, 97, 12547–12552. [Google Scholar] [CrossRef] [Green Version]
- Li, M.; Chen, D.; Shiloh, A.; Luo, J.; Nikolaev, A.Y.; Qin, J.; Gu, W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416, 648–653. [Google Scholar] [CrossRef]
- Ito, A.; Lai, C.H.; Zhao, X.; Saito, S.; Hamilton, M.H.; Appella, E.; Yao, T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001, 20, 1331–1340. [Google Scholar] [CrossRef] [Green Version]
- Feng, X.H.; Liang, Y.Y.; Liang, M.; Zhai, W.; Lin, X. Direct Interaction of c-Myc with Smad2 and Smad3 to Inhibit TGF-beta-Mediated Induction of the CDK Inhibitor p15(Ink4B). Mol. Cell. 2016, 63, 1089. [Google Scholar] [CrossRef] [PubMed]
- Sherr, C.J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2, 103–112. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Xiong, Y.; Yarbrough, W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92, 725–734. [Google Scholar] [CrossRef] [Green Version]
- Zhou, B.P.; Liao, Y.; Xia, W.; Spohn, B.; Lee, M.H.; Hung, M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001, 3, 245–252. [Google Scholar] [CrossRef]
- Ashcroft, M.; Ludwig, R.L.; Woods, D.B.; Copeland, T.D.; Weber, H.O.; MacRae, E.J.; Vousden, K.H. Phosphorylation of HDM2 by Akt. Oncogene 2002, 21, 1955–1962. [Google Scholar] [CrossRef] [Green Version]
- Gottlieb, T.M.; Leal, J.F.; Seger, R.; Taya, Y.; Oren, M. Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 2002, 21, 1299–1303. [Google Scholar] [CrossRef]
- Ogawara, Y.; Kishishita, S.; Obata, T.; Isazawa, Y.; Suzuki, T.; Tanaka, K.; Masuyama, N.; Gotoh, Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol Chem. 2002, 277, 21843–21850. [Google Scholar] [CrossRef] [Green Version]
- Meek, D.W.; Anderson, C.W. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 2009, 1, a000950. [Google Scholar] [CrossRef] [Green Version]
- Maya, R.; Balass, M.; Kim, S.T.; Shkedy, D.; Leal, J.F.; Shifman, O.; Moas, M.; Buschmann, T.; Ronai, Z.; Shiloh, Y.; et al. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 2001, 15, 1067–1077. [Google Scholar] [CrossRef] [Green Version]
- Qi, S.M.; Cheng, G.; Cheng, X.D.; Xu, Z.; Xu, B.; Zhang, W.D.; Qin, J.J. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? Front. Cell Dev. Biol. 2020, 8, 233. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Wang, X.; Wang, G.; Yang, Y.; Yuan, Y.; Ouyang, L. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy. Eur. J. Med. Chem. 2019, 176, 92–104. [Google Scholar] [CrossRef] [PubMed]
- Yee-Lin, V.; Pooi-Fong, W.; Soo-Beng, A.K. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Rev. Med. Chem. 2018, 18, 173–183. [Google Scholar] [CrossRef] [PubMed]
- Inoue, K.; Fry, E.A.; Frazier, D.P. Transcription factors that interact with p53 and Mdm2. Int. J. Cancer 2016, 138, 1577–1585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okamoto, K.; Kashima, K.; Pereg, Y.; Ishida, M.; Yamazaki, S.; Nota, A.; Teunisse, A.; Migliorini, D.; Kitabayashi, I.; Marine, J.C.; et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell Biol. 2005, 25, 9608–9620. [Google Scholar] [CrossRef] [Green Version]
- LeBron, C.; Chen, L.; Gilkes, D.M.; Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006, 25, 1196–1206. [Google Scholar] [CrossRef] [Green Version]
- Pereg, Y.; Lam, S.; Teunisse, A.; Biton, S.; Meulmeester, E.; Mittelman, L.; Buscemi, G.; Okamoto, K.; Taya, Y.; Shiloh, Y.; et al. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol. Cell Biol. 2006, 26, 6819–6831. [Google Scholar] [CrossRef] [Green Version]
- Jin, J.; Smith, F.D.; Stark, C.; Wells, C.D.; Fawcett, J.P.; Kulkarni, S.; Metalnikov, P.; O’Donnell, P.; Taylor, P.; Taylor, L.; et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr. Biol. 2004, 14, 1436–1450. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Sun, Y. Targeting p53 for Novel Anticancer Therapy. Transl Oncol. 2010, 3, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Ashcroft, M.; Taya, Y.; Vousden, K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell Biol. 2000, 20, 3224–3233. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.X.; Dai, M.S.; Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282, 8052–8059. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.X.; Dai, M.S.; Lu, H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J. Biol. Chem. 2008, 283, 12387–12392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhat, K.P.; Itahana, K.; Jin, A.; Zhang, Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004, 23, 2402–2412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, W.; Qiu, Z.; Gao, N.; Wang, L.; Cui, H.; Qian, Y.; Jiang, L.; Luo, J.; Yi, Z.; Lu, H.; et al. PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53-MDM2 loop. Nucleic Acids Res. 2011, 39, 2234–2248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dai, M.S.; Lu, H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004, 279, 44475–44482. [Google Scholar] [CrossRef] [Green Version]
- Lohrum, M.A.; Ludwig, R.L.; Kubbutat, M.H.; Hanlon, M.; Vousden, K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3, 577–587. [Google Scholar] [CrossRef] [Green Version]
- Cao, B.; Fang, Z.; Liao, P.; Zhou, X.; Xiong, J.; Zeng, S.; Lu, H. Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit. Oncotarget 2017, 8, 90651–90661. [Google Scholar] [CrossRef] [Green Version]
- Dai, M.S.; Zeng, S.X.; Jin, Y.; Sun, X.X.; David, L.; Lu, H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell Biol. 2004, 24, 7654–7668. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Wang, J.; Yuan, Y.; Zhang, W.; Guan, W.; Wu, Z.; Jin, C.; Chen, H.; Zhang, L.; Yang, X.; et al. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res. 2010, 38, 6544–6554. [Google Scholar] [CrossRef]
- Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 2013, 32, 388–396. [Google Scholar] [CrossRef] [Green Version]
- Xiong, X.; Zhao, Y.; He, H.; Sun, Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011, 30, 1798–1811. [Google Scholar] [CrossRef] [Green Version]
- Fahraeus, R.; Olivares-Illana, V. MDM2’s social network. Oncogene 2014, 33, 4365–4376. [Google Scholar] [CrossRef]
- Zheng, J.; Lang, Y.; Zhang, Q.; Cui, D.; Sun, H.; Jiang, L.; Chen, Z.; Zhang, R.; Gao, Y.; Tian, W.; et al. Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation. Genes Dev. 2015, 29, 1524–1534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Q.; Xiao, H.; Chai, S.C.; Hoang, Q.Q.; Lu, H. Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation. J. Biol. Chem. 2011, 286, 38264–38274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vousden, K.H.; Ryan, K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9, 691–700. [Google Scholar] [CrossRef] [PubMed]
- Espinoza, J.A.; Zisi, A.; Kanellis, D.C.; Carreras-Puigvert, J.; Henriksson, M.; Huhn, D.; Watanabe, K.; Helleday, T.; Lindstrom, M.S.; Bartek, J. The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death Differ. 2020, 27, 773–789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Golomb, L.; Volarevic, S.; Oren, M. p53 and ribosome biogenesis stress: The essentials. FEBS Lett. 2014, 588, 2571–2579. [Google Scholar] [CrossRef]
- Sloan, K.E.; Bohnsack, M.T.; Watkins, N.J. The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress. Cell Rep. 2013, 5, 237–247. [Google Scholar] [CrossRef] [Green Version]
- Jung, J.H.; Lee, H.J.; Kim, J.H.; Sim, D.Y.; Im, E.; Kim, S.; Chang, S.; Kim, S.H. Colocalization of MID1IP1 and c-Myc is Critically Involved in Liver Cancer Growth via Regulation of Ribosomal Protein L5 and L11 and CNOT2. Cells 2020, 9, 985. [Google Scholar] [CrossRef] [Green Version]
- Liao, J.M.; Zhou, X.; Gatignol, A.; Lu, H. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex. Oncogene 2014, 33, 4916–4923. [Google Scholar] [CrossRef] [Green Version]
- Fang, Z.; Cao, B.; Liao, J.M.; Deng, J.; Plummer, K.D.; Liao, P.; Liu, T.; Zhang, W.; Zhang, K.; Li, L.; et al. SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer. Elife 2018, 7, e31275. [Google Scholar] [CrossRef]
- Dai, M.S.; Sun, X.X.; Lu, H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol. Cell Bio. 2008, 28, 4365–4376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lo, D.; Lu, H. Nucleostemin: Another nucleolar “Twister” of the p53-MDM2 loop. Cell Cycle 2010, 9, 3227–3232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, G.; Zhang, Y.W.; Lee, J.H.; Zeng, S.X.; Wang, Y.V.; Luo, Z.; Dong, X.C.; Viollet, B.; Wahl, G.M.; Lu, H. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol. Cell Biol. 2014, 34, 148–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18, 283–293. [Google Scholar] [CrossRef]
- Wang, Y.V.; Leblanc, M.; Wade, M.; Jochemsen, A.G.; Wahl, G.M. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 2009, 16, 33–43. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.; Kim, T.H.; Franklin, D.A.; Zhang, Y. Protection against High-Fat-Diet-Induced Obesity in MDM2(C305F) Mice Due to Reduced p53 Activity and Enhanced Energy Expenditure. Cell Rep. 2017, 18, 1005–1018. [Google Scholar] [CrossRef]
- Rodor, J.; FitzPatrick, D.R.; Eyras, E.; Caceres, J.F. The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development. RNA Biol. 2017, 14, 45–57. [Google Scholar] [CrossRef]
- Dou, X.Q.; Chen, X.J.; Zhou, Q.; Wen, M.X.; Zhang, S.Z.; Zhang, S.Q. miR-335 modulates Numb alternative splicing via targeting RBM10 in endometrial cancer. Kaohsiung J. Med. Sci. 2020, 36, 171–177. [Google Scholar] [CrossRef] [Green Version]
- Sutherland, L.C.; Wang, K.; Robinson, A.G. RBM5 as a putative tumor suppressor gene for lung cancer. J. Thorac. Oncol. 2010, 5, 294–298. [Google Scholar] [CrossRef] [Green Version]
- Yang, Z.T.; An, F.; Hu, J.D.; Zhao, W.H. Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression. Eur. Rev. Med. Pharmacol Sci. 2019, 23, 3284–3290. [Google Scholar]
- Guo, L.Y.; Qin, C.F.; Zou, H.X.; Song, M.Y.; Gong, M.L.; Chen, C. LncRNA AB073614 promotes the proliferation and inhibits apoptosis of cervical cancer cells by repressing RBM5. Eur. Rev. Med. Pharmacol Sci. 2020, 24, 7201. [Google Scholar] [PubMed]
- Wang, K.; Ubriaco, G.; Sutherland, L.C. RBM6-RBM5 transcription-induced chimeras are differentially expressed in tumours. BMC Genom. 2007, 8, 348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Q.; Wang, F.; Zhong, W.; Ling, H.; Wang, J.; Cui, J.; Xie, T.; Wen, S.; Chen, J. RNA-binding protein RBM6 as a tumor suppressor gene represses the growth and progression in laryngocarcinoma. Gene 2019, 697, 26–34. [Google Scholar] [CrossRef]
- Sun, X.; Jia, M.; Sun, W.; Feng, L.; Gu, C.; Wu, T. Functional role of RBM10 in lung adenocarcinoma proliferation. Int. J. Oncol 2019, 54, 467–478. [Google Scholar] [CrossRef] [Green Version]
- Imielinski, M.; Berger, A.H.; Hammerman, P.S.; Hernandez, B.; Pugh, T.J.; Hodis, E.; Cho, J.; Suh, J.; Capelletti, M.; Sivachenko, A.; et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150, 1107–1120. [Google Scholar] [CrossRef] [Green Version]
- Vinayanuwattikun, C.; Le Calvez-Kelm, F.; Abedi-Ardekani, B.; Zaridze, D.; Mukeria, A.; Voegele, C.; Vallee, M.; Purnomosari, D.; Forey, N.; Durand, G.; et al. Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. Sci. Rep. 2016, 6, 31628. [Google Scholar] [CrossRef]
- Furukawa, T.; Kuboki, Y.; Tanji, E.; Yoshida, S.; Hatori, T.; Yamamoto, M.; Shibata, N.; Shimizu, K.; Kamatani, N.; Shiratori, K. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 2011, 1, 161. [Google Scholar] [CrossRef] [Green Version]
- Witkiewicz, A.K.; McMillan, E.A.; Balaji, U.; Baek, G.; Lin, W.C.; Mansour, J.; Mollaee, M.; Wagner, K.U.; Koduru, P.; Yopp, A.; et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015, 6, 6744. [Google Scholar] [CrossRef]
- Giannakis, M.; Mu, X.J.; Shukla, S.A.; Qian, Z.R.; Cohen, O.; Nishihara, R.; Bahl, S.; Cao, Y.; Amin-Mansour, A.; Yamauchi, M.; et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016, 17, 1206. [Google Scholar] [CrossRef] [PubMed]
- Ibrahimpasic, T.; Xu, B.; Landa, I.; Dogan, S.; Middha, S.; Seshan, V.; Deraje, S.; Carlson, D.L.; Migliacci, J.; Knauf, J.A.; et al. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clin. Cancer Res. 2017, 23, 5970–5980. [Google Scholar] [CrossRef] [Green Version]
- Zhao, J.; Sun, Y.; Huang, Y.; Song, F.; Huang, Z.; Bao, Y.; Zuo, J.; Saffen, D.; Shao, Z.; Liu, W.; et al. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci. Rep. 2017, 7, 40488. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Bacon, M.L.; Tessier, J.J.; Rintala-Maki, N.D.; Tang, V.; Sutherland, L.C. RBM10 Modulates Apoptosis and Influences TNF-alpha Gene Expression. J. Cell Death 2012, 5, 1–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jin, X.; Di, X.; Wang, R.; Ma, H.; Tian, C.; Zhao, M.; Cong, S.; Liu, J.; Li, R.; Wang, K. RBM10 inhibits cell proliferation of lung adenocarcinoma via RAP1/AKT/CREB signalling pathway. J. Cell Mol. Med. 2019, 23, 3897–3904. [Google Scholar] [CrossRef] [Green Version]
- Jung, J.H.; Lee, H.; Cao, B.; Liao, P.; Zeng, S.X.; Lu, H. RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Oncogene 2020, 39, 1031–1040. [Google Scholar] [CrossRef]
- Jiang, Y.; Zhang, M.; Qian, Y.; Xu, E.; Zhang, J.; Chen, X. Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J. Biol. Chem. 2014, 289, 3164–3175. [Google Scholar] [CrossRef] [Green Version]
- Ye, J.; Liang, R.; Bai, T.; Lin, Y.; Mai, R.; Wei, M.; Ye, X.; Li, L.; Wu, F. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2018, 37, 212. [Google Scholar] [CrossRef]
- Yang, Z.; Qu, C.B.; Zhang, Y.; Zhang, W.F.; Wang, D.D.; Gao, C.C.; Ma, L.; Chen, J.S.; Liu, K.L.; Zheng, B.; et al. Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene 2019, 38, 2516–2532. [Google Scholar] [CrossRef] [Green Version]
- Collins, K.M.; Kainov, Y.A.; Christodolou, E.; Ray, D.; Morris, Q.; Hughes, T.; Taylor, I.A.; Makeyev, E.V.; Ramos, A. An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion. Nucleic Acids Res. 2017, 45, 6761–6774. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jung, J.H.; Lee, H.; Zeng, S.X.; Lu, H. RBM10, a New Regulator of p53. Cells 2020, 9, 2107. https://doi.org/10.3390/cells9092107
Jung JH, Lee H, Zeng SX, Lu H. RBM10, a New Regulator of p53. Cells. 2020; 9(9):2107. https://doi.org/10.3390/cells9092107
Chicago/Turabian StyleJung, Ji Hoon, Hyemin Lee, Shelya X Zeng, and Hua Lu. 2020. "RBM10, a New Regulator of p53" Cells 9, no. 9: 2107. https://doi.org/10.3390/cells9092107